Important Information About JESDUVROQ (daprodustat) tablets

As part of our regular course of business, GSK continually assesses our products and pipeline to ensure we’re providing the greatest potential health impact and benefit for patients. After careful consideration, including the availability of alternative treatment options for patients, GSK has made the decision to withdraw JESDUVROQ (daprodustat) tablets from the US market. This voluntary action is NOT related to the safety or efficacy of JESDUVROQ.

FDA has posted in the Federal Register the withdrawal of the JESDUVROQ (daprodustat) tablets new drug application, effective on 12/19/2024. We will support providers as they work to appropriately transition their patients to other therapeutic options.